The approval applies to individuals with confirmed amyloid pathology who are apolipoprotein E (ApoE4) heterozygotes or non-carriers. Kisunla, administered as a monthly infusion, is already available in several The post Lilly secures EC approval for Kisunla to treat Alzheimer’s disease appeared first on Pharmaceutical Business review.